Dandjinou M, et al. - A nested case-control study was done within the Quebec Pregnancy Cohort, a Canadian provincial database that comprises of data on all pregnancies and children in Quebec from January 1998 to December 2015 in order to ascertain the correlation between antidepressant (AD) classes, types and duration of use during pregnancy and the risk of gestational DM (GDM). A total of 9,741 women among 20,905 cases and 209,050 matched controls, were exposed to ADs. When adjusting for potential confounders, AD use was related to a progressed risk of GDM and venlafaxine and amitriptyline were also correlated with a heightened risk of GDM. Furthermore, especially for serotonin-norepinephrine reuptake inhibitors, tricyclic ADs and combined use of two AD classes, the risk of GDM was enhanced with a more prolonged duration of AD use. For selective serotonin reuptake inhibitors, no statistically important correlation was seen. Therefore, the verdicts infer that ADs—and specifically venlafaxine and amitriptyline—were correlated with a heightened risk of GDM.